ArticleObstetrics and gynecology2009
Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting.
Article in Obstetrics and gynecology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.The Cochrane database of systematic reviews · 2013Pooled it
- American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.Journal of lower genital tract disease · 2012Pooled it
- American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.CA: a cancer journal for cliniciansGuideline
- Effect of Mailed Human Papillomavirus Test Kits vs Usual Care Reminders on Cervical Cancer Screening Uptake, Precancer Detection, and Treatment: A Randomized Clinical Trial.JAMA network open · 2019Trial
- Type-specific HPV and Pap test results among low-income, underserved women: providing insights into management strategies.American journal of obstetrics and gynecology · 2014Trial
- Overview of the CDC Cervical Cancer (Cx3) Study: an educational intervention of HPV testing for cervical cancer screening.Journal of women's health (2002) · 2014Trial
- Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2011Trial
- Correlation analysis of bacterial vaginosis with HPV infection and different grades of cervical lesions.BMC women's health · 2026Article
- Role of non-coding RNAs in human-papillomavirus-associated cutaneous neoplasms.Archives of virology · 2025Review
- Clinical implementation of a cervical cancer screening program via co-testing at a university hospital.PloS one · 2022Article
- Harmless or Threatening? Interpreting the Results of Molecular Diagnosis in the Context of Virus-Host Relationships.Frontiers in microbiology · 2021Review
- Sample-weighted semiparametric estimation of cause-specific cumulative risk and incidence using left- or interval-censored data from electronic health records.Statistics in medicine · 2020Article
- Molecular mechanisms in progression of HPV-associated cervical carcinogenesis.Journal of biomedical science · 2019Review
- Application of p16/Ki-67 dual-staining cytology in cervical cancers.Journal of Cancer · 2019Review
- The potential of RNA as a target for national screening of pre-cancer.Journal of public health in Africa · 2018Article
- What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study.International journal of cancer · 2018Article
- Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study.The Lancet. Public health · 2018Article
- Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system.Contemporary clinical trials · 2018Article
- Surveillance of high-grade cervical cancer precursors (CIN III/AIS) in four population-based cancer registries, United States, 2009-2012.Preventive medicine · 2017Article
- FLEXIBLE RISK PREDICTION MODELS FOR LEFT OR INTERVAL-CENSORED DATA FROM ELECTRONIC HEALTH RECORDS.The annals of applied statistics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo estimate the 5-year age group-specific test positives for Pap tests and human papillomavirus (HPV) testing in a large, general screening population of women 30 and older.
methodsUsing data from Kaiser Permanente Northern California, a large health maintenance organization that introduced cotesting in 2003, we evaluated the cotesting results overall and by 5-year age groups. Women (n=580,289) who opted for and underwent cotesting (n cotests=812,598) between January 2003 and April 2008 were included in the analysis. Pap tests interpreted as atypical squamous cells of undetermined significance (ASC-US) or more severe were considered to be positive. Women were tested for carcinogenic HPV using an assay approved by the U.S. Food and Drug Administration. Binomial exact 95% confidence intervals (CIs) were calculated.
resultsOverall, 6.27% (95% CI 6.21-6.32%) of cotests were carcinogenic HPV positive, and only 3.99% (95% CI 3.94-4.03%) cotests had normal cytology and were carcinogenic HPV positive. By comparison, 5.18% (95% CI 5.13-5.23%) of cotests had ASC-US or more severe cytology, and 2.87% (95% CI 2.84-2.91%) of cotests had ASC-US or more severe cytology and were carcinogenic HPV negative.
conclusionIn a general screening population, concerns about excessive HPV test positives among women aged 30 years and older are not borne out.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.